Merck & Co., Inc. (MRK)

Revenue

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Keytruda/Keytruda Qlex Revenue	32.51B	31.68B	29.48B
Keytruda/Keytruda Qlex Revenue Growth	2.61%	7.46%	17.88%
Gardasil/Gardasil 9 Revenue	4.98B	5.23B	8.58B
Gardasil/Gardasil 9 Revenue Growth	-4.93%	-39.03%	-3.41%
Januvia/Janumet Revenue	2.32B	2.54B	2.27B
Januvia/Janumet Revenue Growth	-8.73%	12.17%	-32.62%
ProQuad/M-M-R II/Varivax Revenue	2.45B	2.45B	2.49B
ProQuad/M-M-R II/Varivax Revenue Growth	-0.04%	-1.37%	4.94%
Bridion Revenue	1.87B	1.84B	1.76B
Bridion Revenue Growth	1.63%	4.37%	-4.23%
Lynparza - Alliance Revenue	1.48B	1.45B	1.31B
Lynparza - Alliance Revenue Growth	2.00%	10.60%	9.34%
Winrevair Revenue	1.69B	1.44B	419.00M
Winrevair Revenue Growth	16.98%	244.39%	-
Lenvima - Alliance Revenue	1.05B	1.05B	1.01B
Lenvima - Alliance Revenue Growth	-0.19%	4.26%	5.21%
Pharmaceutical Revenue	58.85B	58.14B	57.40B
Pharmaceutical Revenue Growth	1.22%	1.29%	7.12%
Animal Health Revenue	6.56B	6.35B	5.88B
Animal Health Revenue Growth	3.19%	8.12%	4.48%
Other Product Revenue	358.00M	515.00M	891.00M
Other Product Revenue Growth	-30.48%	-42.20%	-1.76%
Revenue (Other)	-48.35B	-47.70B	-47.32B
Revenue (Total)	65.77B	65.01B	64.17B
Revenue (Total) Growth	1.16%	1.31%	6.74%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
United States Revenue	37.15B	36.51B	32.28B
United States Revenue Growth	1.76%	13.11%	13.33%
Europe, Middle East and Africa Revenue	15.02B	14.58B	14.04B
Europe, Middle East and Africa Revenue Growth	2.99%	3.84%	5.94%
Latin America Revenue	3.49B	3.41B	3.46B
Latin America Revenue Growth	2.40%	-1.42%	12.09%
China Revenue	1.63B	1.94B	5.49B
China Revenue Growth	-16.09%	-64.71%	-19.23%
Asia Pacific (other than China and Japan) Revenue	3.03B	2.98B	3.06B
Asia Pacific (other than China and Japan) Revenue Growth	1.64%	-2.45%	-5.18%
Japan Revenue	2.60B	2.71B	3.28B
Japan Revenue Growth	-4.21%	-17.35%	3.67%
Other Geographic Revenue	2.85B	2.88B	2.56B
Other Geographic Revenue Growth	-0.87%	12.47%	21.63%
Revenue (Other)	-1.00M	-	-
Revenue (Total)	65.77B	65.01B	64.17B
Revenue (Total) Growth	1.16%	1.31%	6.74%

EBT

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Pharmaceutical Segment Profit	46.56B	45.75B	44.53B
Pharmaceutical Segment Profit Growth	1.76%	2.74%	14.54%
Animal Health Segment Profit	2.22B	2.13B	1.94B
Animal Health Segment Profit Growth	4.13%	9.96%	11.57%
Other Segment Profit	-9.13B	-26.82B	-26.54B

Data Source: Fiscal.ai Last updated: May 4, 2026

Financial data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 10, 2026

Data Sources Report a data error